35265-81-7

Basic information

• Product Name: 7-Methylthieno[3,2-d]pyrimidine-2,4-diol
• Synonyms: 7-Methylthieno[3,2-d]pyrimidine-2,4-diol;7-Methylthieno[3,2-d]pyrimidin-2,4(1H,3H)-dione;7-Methyl-1H,2H,3H,4H-thieno[3,2-d]pyriMidine-2,4-dione;Thieno[3,2-d]pyriMidine-2,4(1H,3H)-dione, 7-Methyl-;7-Methylthieno[3,2-d]pyriMidine-2,4(1H,3H)-dione;7-Methylthieno[3,2-d]pyrimidine-2,4-diol-2;7-methyl-1H-thieno[3,2-d]pyrimidine-2,4-dion
• CAS NO: 35265-81-7
• Molecular Formula: C₇H₆N₂O₂S
• Molecular Weight: 182.2
• Mol File: 35265-81-7.mol
• Article Data: 16

Chemical Properties

• Appearance: /
• Density: 1.433
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 7-Methylthieno[3,2-d]pyrimidine-2,4-diol(CAS DataBase Reference)
• NIST Chemistry Reference: 7-Methylthieno[3,2-d]pyrimidine-2,4-diol(35265-81-7)
• EPA Substance Registry System: 7-Methylthieno[3,2-d]pyrimidine-2,4-diol(35265-81-7)

Safety Data

• Hazardous Substances Data: 35265-81-7(Hazardous Substances Data)

Usage

General Description

7-Methylthieno[3,2-d]pyrimidine-2,4-diol is a chemical compound with the molecular formula C6H6N2OS. It is a heterocyclic molecule that contains a thieno ring fused to a pyrimidine ring, with a methyl group and two hydroxyl groups attached at specific positions. 7-Methylthieno[3,2-d]pyrimidine-2,4-diol is of interest in medicinal chemistry and pharmaceutical research, as it possesses potential biological activities and is being investigated for its therapeutic potential. It may also have use in the development of novel drugs and pharmaceuticals due to its unique structure and potential pharmacological properties. Additionally, it is important to handle this compound with care, as it may pose health and environmental risks if mishandled.

Upstream product

• 57-13-6 urea 
• 85006-31-1 3-amino-4-methyl-2-thiophenecarboxylic acid methyl ester 
• 1026676-57-2 4-Methyl-3-ureido-thiophene-2-carboxylic acid ethyl ester 
• 955979-03-0 4-methyl-3-ureido-thiophene-2-carboxylic acid methyl ester 
• 3019-71-4 Trichloroacetyl isocyanate 
• 590-28-3 potassium cyanate 
• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 

Downstream Products

• 35265-83-9 2,4-dichloro-7-methyl-thieno[3,2-d]pyrimidine 
• 1356016-35-7 2-chloro-thieno[3,2-d]pyrimidine-7-carbaldehyde 
• 1356017-09-8 2-Chloro-thieno[3,2-d]pyrimidine-7-carboxylic acid (3,4-dimethoxy-phenyl)-amide 
• 1356017-78-1 2-chloro-thieno[3,2-d]pyrimidine-7-carboxylic acid (3,4,5-trimethoxy-phenyl)-amide 
• 1356017-12-3 2-chloro-thieno[3,2-d]pyrimidine-7-carboxylic acid(2,4-dimethoxy-phenyl)-amide 
• 35265-88-4 4-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)morpholine 
• 955979-02-9 2-chloro-7-methyl-4-morpholinothieno[3,2-d]-pyrimidine-6-carbaldehyde 

Relevant articles and documents

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

PYRIMIDINE AMIDE COMPOUNDS AND USE THEREOF

Disclosed are compounds of formula (I) below or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof: (I), in which each of variables each of variables R, R1, R2, X1, X2, X3 and n is defined herein. Also disclosed is a method for treating a cancer with a compound of formula (I) or a salt thereof and a pharmaceutical composition containing same.

Discovery of novel and potent PARP/PI3K dual inhibitors for the treatment of cancer

PARP inhibitors have achieved great success in cancers with BRCA mutations, but only a small portion of patients carry BRCA mutations, which results in their narrow indication spectrum. Recently, emerging evidence has demonstrated that combinations of PARP and PI3K inhibitors could evoke unanticipated synergistic effects in various cancers, even including BRCA-proficient ones. In this work, a series of PARP/PI3K dual inhibitors were designed, synthesized, and evaluated for their biological activities. It was found that compounds 9a and 23a exhibited excellent inhibitory activities against PARP-1 (9a: IC50 = 1.57 nM, 23a: IC50 = 0.91 nM) and PI3Kα (9a: IC50 = 2.0 nM, 23a: IC50 = 1.5 nM), and showed promising antiproliferative activities against both BRCA-deficient (HCT-116, HCC-1937) and BRCA-proficient (SW620, MDA-MB-231/468) tumor cells. 9a and 23a also exhibited considerable in vivo antitumor efficacy in an MDA-MB-468 xenograft mouse model, with TGI values of 56.39% and 48.77%, respectively. Additionally, 23a possessed promising profiles including high kinase selectivity and low cardiotoxicity. Overall, this work indicates 9a and 23a might be potential PARP/PI3K dual inhibitors for cancer therapy and deserve further research.